CJC-1295: the 2006 study on long-lasting GHRH signaling

CJC-1295 is a modified version of GHRH(1-29) built to last much longer in circulation. The design attaches it to albumin in the blood, which is what stretches its half-life from minutes to days. Key papers: 1. Teichman et al. (JCEM, 2006), the human study showing prolonged GH and IGF-1 rises after single doses in healthy adults. https://doi.org/10.1210/jc.2005-1536 2. Cervini et al. (J Med Chem, 1998), structure-activity work on GHRH(1-29), the backbone CJC-1295 is built on. https://doi.org/10.1021/jm970618s 3. Henninge et al. (Drug Test Anal, 2010), on detecting CJC-1295 in plasma, from the anti-doping side. https://doi.org/10.1002/dta.233 One thing that confuses a lot of discussion: the compound in the 2006 study includes the albumin-binding group. Material sold as "CJC-1295 without DAC" is a different, short-acting molecule (often called modified GRF 1-29), and the long half-life data doesn't apply to it. For discussion: what other published data exists beyond the 2006 trial? The full write-up is in Guides: CJC-1295.